We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Filtering Donor Blood Reduces Complications in the Recipient

By LabMedica International staff writers
Posted on 06 Jul 2010
When foreign white cells were filtered from donor blood, there were dramatically fewer cardiopulmonary complications in recipients.

An observational study was conducted during the seven years before and after 2000, when the University of Rochester Medical Center (URMC; Rochester, NY, USA) introduced universal leukoreduction, a process that filters the white cells from blood to be used for transfusions. More...
Investigators looked at the number of reports of transfusion reactions during the 14-year period, and divided them by the total number of blood components transfused (778, 559).

Rates of acute, transfusion-related lung injury dropped 83 % in the years after filtering took place, and transfusion-associated circulatory overload declined 49 %, when compared to the rates prior to the year 2000. Both conditions are rare, but are among the most common causes of death following a transfusion.

"These data are very exciting because we described two unexpected and unexplained associations between adverse reactions and leukoreduction," said Neil Blumberg, M.D. who led the study. "However, our observations do not prove cause and effect, and therefore require further investigation before we can say with certainty that leukoreduction is responsible for so many fewer cardiopulmonary complications."

The [U.S.] Centers for Disease Control and Prevention (Atlanta, GA, USA) is introducing a new blood surveillance system to track severe transfusion reactions, which should provide more detailed information to support or refute the URMC study.

The study appears in the June 18, 2010, online edition of the journal Transfusion.

Work done at URMC also has supported keeping transfusions to an absolute minimum. Dr. Blumberg's evidence-based stance on the judicious use of transfusions and safer techniques has contributed greatly to the national and international dialogue on reducing in-hospital infections rates and controlling costs.

Related Links:
University of Rochester Medical Center
U.S. Centers for Disease Control and Prevention




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.